Encore? FDA Could Come Close To Record 2012 NME Count This Year
Executive Summary
With 19 novel agents approved so far in 2013 and a full slate of candidates under review, the recovery in novel agent approvals after the doldrums of the 2000s is likely to continue even if the agency falls short of last year’s 45 approvals. Watch for action on the first “breakthrough” therapies submitted and advances in hepatitis C treatment.
You may also be interested in...
Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA
While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.
Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA
While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.
First-In-Class Drugs Are True Barometer Of Industry Innovation, FDA Says
The agency suggests that categorizing approved drugs by level of novelty and tracking approvals by category is a better metric than NME count and should be the basis for assessment of the programs created by FDASIA to speed development of innovative products.